Treatment-resistant depression (TRD) in particular is associated with a heightened inflammatory response [23], and treatment with the anti-inflammatory tumor necrosis factor-alpha (TNF-α) antagonist, infliximab, has been shown to improve TRD. Here, TNF is linked to treatment resistant depression.